-
The application for YK012 IND, the innovative double antibody of Yikester, was approved and will enter the phase I clinical trial stage
Recently, the bispecific antibody YK012 (acceptance number: CXSL2200041) independently developed by Yikester (Beijing) Pharmaceutical Technology Development Co., Ltd. was officially approved by the Dr
2021/11/10 admin 281
-
Obtained special fund support from Beijing Municipal Commission of Science and Technology for the cultivation of pharmaceutical innovative varieties and platforms
In March 2021, the "new generation of safe, high-yield and long-acting leukemia bispecific antibody pre-clinical research" project declared by our company was approved by the municipal sc
2021/03/10 admin 41
-
The company won the second prize in the first "Future Star" biomedical innovation transformation project competition in 2021
On January 6, under the guidance of the Beijing Municipal Commission of Science and Technology, the Administrative Committee of the Beijing Economic an
2021/01/10 admin 34
-
Series A financing of Detong Capital and Qianhai Master Fund
In December 2020, Ecotech (Beijing) Pharmaceutical Technology Development Co., Ltd. completed a round A financing of tens of millions of yuan, which was jointly led by Detong Capital and Qianhai Maste
2020/12/10 admin 76
-
National high-tech enterprises
In 2020, in this period of epidemic, we will fight the epidemic together and unite as one. The epidemic is merciless and there is love in the world. With the strong support of the state and the effort
2020/10/10 admin 36
-
Top 50 of the "Maker Beijing 2020" epidemic prevention and control special competition
Recently, the "Maker China" Beijing SME Innovation and Entrepreneurship Competition and the "Maker Beijing 2020" Innovation and Entrepreneurship Competition were officially launche
2020/09/10 admin 38
